Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Sygnis AG. (12/12/14). "Press Release: Sygnis AG Successfully Completes Rights Offering and Private Placement". Heidelberg.

Organisations Organisation Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
  Group Genetrix (ES) (Group)
  Organisation 2 BioCat GmbH
Products Product TruePrime™ Single Cell WGA kit
  Product 2 investment banking
Index terms Index term Genetrix (ES)–SEVERAL: investment, 201412 rights offering + private placement of Sygnis AG €4.95m with 2.476m new shares €2/share
  Index term 2 BioCat GmbH–Genetrix (ES): TruePrime, 201412– distribution non-excl of Sygnis’ TruePrime Single Cell WGA kit by BioCat
Person Person de la Huerta Martinez, Pilar (Sygnis Pharma 201303– CEO + CFO before Genetrix CEO before Zeltia)
     


> Offering significantly over-subscribed

> Gross proceeds amounted to € 4.95 million.

> Evaluation by an industry leading partner for use on own Next Generation Sequencing (NGS) platform ongoing

> Company will use proceeds to develop and commercialize its proprietary product portfolio


SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that the Company has successfully completed its rights offering.

Subscription ratio in the rights offering was 13:3 which meant thirteen existing shares entitled the shareholder to subscribe for three new shares with the opportunity to oversubscribe. The subscription price was € 2.00 per share. New shares that were not subscribed in the course of the rights offering by existing shareholders were offered to selected German and international institutional investors in a private placement at a purchase price equivalent to the subscription price. The transaction was planned for a total volume of up to 2,475,678 new shares against cash. All of these shares were allocated.

The key advantages of the TruePrime™ product line include complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias compared to methods using random synthetic primers and an exquisite reproducibility when DNA is amplified from single mammalian cells. Moreover, TruePrime™ shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and IonTorrent. The Company plans to launch the first kit for DNA amplification from single cells in January of 2015.

By the successful transaction, the Company’s share capital increases from € 10,822,662.00 to € 13,298,340.00 by issuing 2,475,678 new shares. The offering utilizes existing authorized capital created by resolution at the Annual General Meeting on July 17, 2014. The new shares carry full dividend rights as of January 1, 2014.

“We are very happy about the successful completion of our rights offering and the private placement. We welcome our old and new shareholders and are very thankful for their trust in SYGNIS,” stated Pilar de la Huerta, CEO and CFO of SYGNIS AG. “The huge interest we saw in this transaction and the resulting significant over-subscription are demonstrating increasing investors‘ confidence in SYGNIS’ product and commercialization strategy and the growth markets we address. With its first proprietary product TruePrime™ Single Cell WGA kit expected to be launched in January 2015 and a first distribution agreement for this product already signed with German BioCat GmbH, SYGNIS is best positioned to benefit from the high growth rates in next generation sequencing for use in oncology research, gene-based personalized healthcare and molecular diagnostics. The transaction provides the Company with the financial flexibility needed to expand its proprietary portfolio of exciting new products and to meet the next milestones in our corporate and commercial development plan.“

SYGNIS plans to use the gross proceeds of € 4.95 million to finance its operating business, the development and commercialization of its proprietary product portfolio.

The capital increase was advised by GBC AG, Augsburg.


For further information please contact:

SYGNIS AG
Pilar de la Huerta, CEO/CFO
Email: pdelahuerta@sygnis.es

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Genetrix (ES) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top